MX2023002984A - Nuevos anticuerpos anti-a2ap y usos de los mismos. - Google Patents

Nuevos anticuerpos anti-a2ap y usos de los mismos.

Info

Publication number
MX2023002984A
MX2023002984A MX2023002984A MX2023002984A MX2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A
Authority
MX
Mexico
Prior art keywords
a2ap
antibodies
novel anti
antigen
binding fragment
Prior art date
Application number
MX2023002984A
Other languages
English (en)
Inventor
Andreas Wilmen
Stefan Heitmeier
Ernst Weber
Hannah Jörissen
Cindy Schulenburg
Julia Glunz
Melanie Fischer
Christoph Thiel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2023002984A publication Critical patent/MX2023002984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une a A2AP humana. El anticuerpo aislado o fragmento de unión a antígeno según la presente invención i) reacciona de forma cruzada con A2AP de conejo y/o cynomolgus, ii) no inhibe la actividad de la plasmina humana, y iii) aumenta la lisis del coágulo mediada por plasmina en presencia de A2AP.
MX2023002984A 2020-09-15 2021-09-13 Nuevos anticuerpos anti-a2ap y usos de los mismos. MX2023002984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196259 2020-09-15
PCT/EP2021/075038 WO2022058261A2 (en) 2020-09-15 2021-09-13 Novel anti-a2ap antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002984A true MX2023002984A (es) 2023-04-10

Family

ID=72521424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002984A MX2023002984A (es) 2020-09-15 2021-09-13 Nuevos anticuerpos anti-a2ap y usos de los mismos.

Country Status (14)

Country Link
US (3) US20240010750A1 (es)
EP (1) EP4214241A2 (es)
JP (2) JP7454106B2 (es)
KR (1) KR20230069171A (es)
CN (1) CN116249719A (es)
AR (1) AR123523A1 (es)
AU (1) AU2021343834A1 (es)
BR (1) BR112023002800A2 (es)
CA (1) CA3194792A1 (es)
IL (1) IL301307A (es)
MX (1) MX2023002984A (es)
PE (1) PE20240214A1 (es)
TW (1) TW202227505A (es)
WO (1) WO2022058261A2 (es)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2266341A1 (en) 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20100137156A1 (en) 2007-03-09 2010-06-03 Leung Shui-On Construction and use of a functionally human antibody library with maximized repertoire diversity

Also Published As

Publication number Publication date
KR20230069171A (ko) 2023-05-18
BR112023002800A2 (pt) 2023-03-21
WO2022058261A3 (en) 2022-06-16
IL301307A (en) 2023-05-01
WO2022058261A2 (en) 2022-03-24
AU2021343834A1 (en) 2023-04-13
CN116249719A (zh) 2023-06-09
US20240034810A1 (en) 2024-02-01
US20240010750A1 (en) 2024-01-11
US20240166766A1 (en) 2024-05-23
JP7454106B2 (ja) 2024-03-21
CA3194792A1 (en) 2022-03-24
AR123523A1 (es) 2022-12-14
EP4214241A2 (en) 2023-07-26
PE20240214A1 (es) 2024-02-16
JP2024063234A (ja) 2024-05-10
TW202227505A (zh) 2022-07-16
JP2023541179A (ja) 2023-09-28

Similar Documents

Publication Publication Date Title
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
ATE461220T1 (de) Anti-egfr-antikörper
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
MX2020009152A (es) Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
CR20220646A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
EA202190235A1 (ru) Антитела к cd33 и способы их применения
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
CR20220288A (es) Anticuerpos contra integrina alfa 11 beta 1
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
WO2006138429A3 (en) Antibodies against hmgb1 and fragments thereof
MX2023002984A (es) Nuevos anticuerpos anti-a2ap y usos de los mismos.
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2020013450A (es) Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.